Acute myocardial infarction complicated by acute heart failure
Conditions
Interventions
rhBNP group:Recombinant Human Brain Natriureted Peptide for Injection
Sponsors
Hengshui People’s Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >=18 years, both male and female; 2. Meet the diagnostic criteria for acute myocardial infarction: dynamic elevation of cardiac injury markers (e.g., serum cardiac troponin) accompanied by at least one evidence of myocardial ischemia (e.g., ischemic symptoms, new ST-T changes on ECG, new pathological Q waves, or imaging evidence); 3. Meet the diagnostic criteria for acute heart failure: typical symptoms or signs of pulmonary or systemic congestion (e.g., dyspnea, orthopnea, moist rales in the lungs, peripheral edema, etc.); significantly elevated natriuretic peptide levels (NT-proBNP >450 ng/L for patients 900 ng/L for those aged 50–75 years, >1800 ng/L for those >75 years, and >1200 ng/L in the presence of renal dysfunction (eGFR =II and NYHA class >II at admission; 5. Written informed consent signed by the patient or their legal representative.
Exclusion criteria
Exclusion criteria: 1. Presence of significant valvular stenosis, hypertrophic or restrictive cardiomyopathy, constrictive pericarditis, or cardiac tamponade; 2. Presence of cardiogenic shock, persistent systolic blood pressure <90 mmHg, or other conditions in which the use of vasodilators is not appropriate; 3. Presence of severe hepatic or renal dysfunction with creatinine clearance <30 mL/min, or requirement for continuous renal replacement therapy (CRRT); 4. Pregnancy, lactation, or planned pregnancy within 3 months; 5. Known or suspected allergy to the investigational product or any of its components; 6. Participation in another clinical study within the past month; 7. History of psychiatric disorders such as depression or anxiety; 8. Any other condition that, in the investigator's opinion, may place the patient at risk.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in NT-proBNP levels at day three of treatment;Change from baseline in Visual Analog Scale for Anxiety (VAS-A) score at hospital discharge; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of adverse events;Changes in Killip cardiac functional classification compared with baseline after 3 days of treatment;Change from baseline in cardiac function parameters (LVEF, LVEDD, E/A ratio, E/e' ratio, etc.) at hospital discharge; | — |
Countries
China
Contacts
Public ContactHuijing Zhang
Hengshui People’s Hospital
Outcome results
None listed